Genetic and Epigenetic of Medullary Thyroid Cancer

Fatemeh Khatami¹ and Seyed Mohammad Tavangar*¹,²

¹Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ²Department of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Received 19 September 2017; revised 25 October 2017; accepted 28 October 2017

ABSTRACT

Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. From the genetic perspective, RET, HRAS, and KRAS are the most important genes that are characterized in MTC. From the epigenetic perspective, Ras-association domain family member 1A, telomerase reverse transcriptase promoter methylations, overexpression of histone methyltransferases, EZH2 and SMYD3, and wide ranging increase and decrease in non-coding RNAs can be responsible for medullary thyroid carcinogenesis. DOI: 10.22034/ibj.22.3.142

Keywords: Thyroid carcinoma, Genetic markers, Proto-oncogene

INTRODUCTION

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that originates from the parafollicular cells (C cells) and produces calcitonin¹. Approximately, a quarter of MTCs are genetic in nature: they are caused by a mutation in the rearranged during transfection (RET) proto-oncogene, a receptor tyrosine kinase gene, which can undergo oncogenic activation through both cytogenetic rearrangement and activation of point mutation. Even though MTC is mostly sporadic (70-80%), some hereditary patterns can be seen in 20-30% of cases: these are classified as familial MTC (FMTC) with autosomal dominant trait²-⁵. High serum concentration of calcitonin and carcinoembryonic antigen is regularly regarded as MTC markers in blood⁶-⁸. It is common knowledge that cancer is the result of genetic changes accumulated in a manner that disturbs the normal homeostatic stability between cell proliferation and cell death⁹,10. In addition to genetic changes, epigenetic events have been considered as key indicators of carcinogenesis. Research on epigenetics has become gradually noticeable with the aim of understanding the role of epigenetic mechanisms in the abnormal events leading to cancer¹¹-¹³. In fact, previous studies on cancer suggest that genetic and epigenetic alterations are two sides of the same coin responsible for morphological changes occurring during cancer progression¹²,¹⁴-¹⁶. Moreover, the notion that early-stage cancer is not as systematically aggressive as late-stage cancer is based on the finding that gene expression profiles is alike in early-stage cancer and fully metastatic cancer¹⁷,¹⁸. Thus, both genetic and epigenetic events correspond to several steps of carcinogenesis. In this review, we summarize current concepts on genetic and epigenetic changes associated with MTC and then discuss their potential relevance as biomarkers for cancer detection, diagnosis, and prognosis.

Hallmarks of genetic MTC

A mutation is a stable modification in the DNA sequence of a given gene, which may alter the normal gene function¹⁹. Mutations can occur anywhere, from a single DNA building block (base pair) to a large...
segment of a chromosome, including multiple genes\(^20\). Some of the mutations are heritable, i.e. they are inherited from a parent and are present throughout a person’s life in virtually every cell in the body. These mutations are called germline mutations since they are present in the parent's egg or sperm cells (germ cells)\(^{20,21}\). Other group of mutations are acquired mutations (or somatic): These happen only at a particular time during a person’s life and are present only in certain cells in the body\(^{20}\). These mutations can be caused by environmental factors, such as ultraviolet radiation from the sun or can occur if an error takes place in DNA replication during cell division. Acquired mutations in somatic cells (cells other than sperm and egg cells) cannot be passed to the next generation\(^{22-25}\).

MTC has been described in two forms: sporadic and hereditary/familial. About one-fourth of MTC patients have one of three different syndromes, which are FMTC, multiple endocrine neoplasia type 2A (MEN 2A), or type 2B (MEN 2B). Around a half of the patients with MEN 2A or MEN 2B develop pheochromocytomas\(^{26-30}\). Moreover, 25% of patients with MEN 2A will possibly develop primary hyperparathyroidism\(^{28,31}\), while patients with MEN 2B develop marfanoid habitus and mucosal/intestinal ganglioneuromatosis\(^{32}\); patients with just FMTC individually develop MTC\(^{29,32}\). In fact proto-oncogene RET germline mutations is presented in 90% of patients with hereditary MTC (FMTC, MEN 2A, or MEN 2B)\(^{33}\). Thus, the entire hereditary syndromes are attributed to the same disease-causing gene\(^{34,35}\). RET proto-oncogene is a tyrosine kinase receptor coding gene, and it is an element of the glial cell line-derived neurotrophic factor (GDNF) family which are classified as extracellular signaling molecules\(^{36}\). Human RET gene with 21 exons is localized on chromosome 10 (10q11.2)\(^{37,38}\). Like other tyrosine kinase receptors, RET is able to motivate several signaling pathways, including RAS/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/AKT, p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) pathways\(^{30,39-44}\). The typical splicing of the RET gene results in three different isoforms. The C-terminal region in RET51, RET43, and RET9 have 51, 43, and 9 amino acids, respectively\(^{45}\). As shown in Figure 1—which is premised on the protein data bank code 2IVT—all RET protein isoforms can be subdivided into three main domains: an N-terminal extracellular domain with four cadherin-like repeats and a cysteine-rich region, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. Phosphorylation of Tyr981 and the additional tyrosinexTyr1015, Tyr1062, and Tyr1096 are not covered by the above structure, though these have been shown to be important for initiation of the intracellular signal transduction processes\(^{36}\).

![Fig. 1. A RET dimer formed between two protein molecules, each spanning amino acids 703-1012 of the RET molecule and covering RET intracellular tyrosine kinase domain. One protein molecule, molecule A, is shown in yellow and the other, molecule B, in grey. The activation loop is colored purple and selected tyrosine residues in green. Part of the activation loop from molecule B is absent. mRET proto-oncogene with three main domains: an N-terminal extracellular domain with four cadherin-like repeats and a cysteine-rich region, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. Phosphorylation of Tyr981 and the additional tyrosines Tyr1015, Tyr1062, and Tyr1096 are not covered by the above structure, though these have been shown to be important for initiation of the intracellular signal transduction processes\(^{36}\).](image-url)

Fig. 1. A RET dimer formed between two protein molecules, each spanning amino acids 703-1012 of the RET molecule and covering RET intracellular tyrosine kinase domain. One protein molecule, molecule A, is shown in yellow and the other, molecule B, in grey. The activation loop is colored purple and selected tyrosine residues in green. Part of the activation loop from molecule B is absent. mRET proto-oncogene with three main domains: an N-terminal extracellular domain with four cadherin-like repeats and a cysteine-rich region, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. Phosphorylation of Tyr981 and the additional tyrosines Tyr1015, Tyr1062, and Tyr1096 are not covered by the above structure, though these have been shown to be important for initiation of the intracellular signal transduction processes\(^{36}\).
neurons; they also cause peripheral autonomy more than renal development and facilitate regulation of spermatogonia differentiation (Fig. 2). In some cases, epigenetic modifications can be stable and can pass on to future generations; mostly, however, they are vigorous modifications in response to environmental stimuli. The major mechanisms responsible for epigenetic regulation are DNA methylation, histone modifications, and non-coding RNAs. The role of epigenetics in MTC is largely defined as hypermethylation of CpG islands in the promoter region of Ras-association domain family member 1A (RASSF1A) and telomerase reverse transcriptase (TERT) genes, overexpression of histone methyltransferases like EZH2 and SMYD3, and microRNAs (miRNAs) expression profile (Fig. 4).

In spite of the fact that RASSF1A gene promoter hypermethylation is linked to more aggressive thyroid cancers, CpG island methylation of tumor-associated genes—such as p16, TSHR, MGMT, and PTEN—have not shown any significant degree of hypermethylation in MTC. Nevertheless, the existence of methylation in the promoter region of TERT gene and consequent variation of DNA copy numbers within a huge cohort study of MTC cases have been documented. In fact, telomerase is a protein responsible for keeping and fixing telomeres of the chromosomes. Its activation by TERT has been increased frequently in many types of cancers, including MTC. Wang and his colleagues have reported that TERT gene hypermethylation is related to high DNA copy number, and MTC patients with higher TERT methylation have lower chances of survival.

Epigenetic control through histone methyltransferases in more aggressive forms of MTC have recently been investigated by Sponzio et al. In fact, the platform of epigenetic regulatory factors and their

Fig. 3. Genetics of medullary thyroid cancer.
mRNA levels profiling in a big cohort of MTC tissues has revealed the fact that overexpression of two histone methyltransferases, *EZH2* and *SMYD3*, is connected with higher risk of metastases, disease consistency, and finally death of patients: These can be prognostic biomarkers for MTC\(^76,88\). Remarkably, gene expression profile was free of *RET* or *RAS* mutations. The most common mutation is related to the *RET* mutation in genetic alteration of MTC tumorigenesis. The transcriptional activity of *RET* is controlled by epigenetic processes as well. It has been demonstrated that in colorectal cancer CpG island methylation of *RET* gene promoter is a potential prognostic marker for stage II of the disease\(^89,90\). Patients with considerable hypermethylated *RET* have worse overall survival compared to those with unmethylated RET promoter\(^91\). Significantly, *RET* expression is regulated by a transcription factor, homeobox B5\(^92\), which is related to the multi-species conserved sequence in the primary intron of the *RET* gene in addition to the higher level of *RET* transcription. Another regulating mechanism of RET transcription level is acetylation because in human neuroblastoma cells with a low *RET* mRNA level, histone deacetylase inhibitor and sodium butyrate cause hyper acetylation and increase the transcription of *RET* gene\(^93\).

MiRNAs are small non-coding RNAs with the lengths of 20-23 nucleotides; they are classified as epigenetic modifiers\(^94\). MiRNAs are non-protein-coding RNAs that alter gene expression through mRNA translation inhibition or by means of the target molecule degrading\(^94,95\). In reality, mutations or abnormal expression of miRNAs are more often related to the pathogenesis of a wide range of cancers because they affect both tumor suppressors and oncogenes\(^96\). In spite of the fact that several studies have highlighted the role of miRNA profiling of MTC and its malignancy (Table 1), due to difficulty in obtaining normal C cells, none of the existing literature has compared miRNA profiles between MTC and normal C cells\(^97\).

Ten miRNAs were shown to have different expression patterns between sporadic MTC and

---

**Table 1.** A list of suggesting microRNA (miRNA) in medullary thyroid cancer

<table>
<thead>
<tr>
<th>Signature of increased and decreased miRNA associated with MTC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increasing miRNA</strong></td>
</tr>
<tr>
<td>miR-183, miR-375, miR-182, miR-29c, miR-130a, miR-138, miR-193-3p, miR-373, miR-498, miR-21, miR-127, miR-224, miR-154, miR-323, miR-551b, miR-370, miR-9, miR-183, miR-375, miR-375, miR-10a</td>
</tr>
<tr>
<td><strong>Decreasing miRNA</strong></td>
</tr>
<tr>
<td>miR-199b-5p, miR-223, let-07i, miR-200b-200c, miR-10a, miR-129-5p, miR-455, and miR-7, miR9</td>
</tr>
</tbody>
</table>
hereditary MTC\textsuperscript{[76]} In correlation with clinical outcomes, high levels of mir-183 and mir-375 were linked to the lateral lymph node and distant metastases\textsuperscript{[78]} Significantly, similarity in miRNA profiles of mir-183, mir-375, and mir-9-3p (mir-9) between primary tumor tissues and lymph node metastasis tissues was observed\textsuperscript{[79]} This was further to the role of mir-9-3p in regulation of autophagy\textsuperscript{[80]} More than that, a comparison of miRNA profiling between primary and metastatic forms of MTC highlighted 10 deregulated miRNAs\textsuperscript{[81-83,98]} There is possibility that the constitutive activation of RET, as a crucial occurrence in MTC tumor genesis, is regulated through epigenetic mechanisms like miRNAs\textsuperscript{[84,99,100]} From genetic point of view, RET mutations in codons 609 (C609X), 618 (C618X), 620 (C620X), 786 (E768D), 804 (V804L), 819 (S891A), 918 (M918T), 833 (A883F), 804 (V804M), 806 (Y806C), 632 (Glu632), 633 (Leu633), and 918 (M918T) as well as HRAS, and KRAS mutations are the most important mutations that cause medullary thyroid carcinogenesis From epigenetic perspective, RASSF1, TERT promoter methylations, histone methyltransferases (EZH2 and SMYD3) overexpression, and wide ranging increase and decrease of non-coding RNAs contribute to medullary thyroid carcinogenesis.

ACKNOWLEDGMENTS

This article is part of a larger project granted by the Iranian organization of the National Institute for Medical Research Development (NIMAD, grant number: 957222).

CONFLICT OF INTEREST None declared.

REFERENCES


Genetic and Epigenetic of MTC
Khatami and Tavangar


